Abstract Objective: Lung cancer (LC) is well known for its high morbidity and mortality rates. The primary objective of this study was to investigate the synergistic effects of hesperetin (HES), a bioactive compound found in sweet oranges, in combination with cisplatin (CDDP), on LC treatment. Methods: Human A549 and mouse Lewis lung cancer (LLC) cell lines were treated with HES, CDDP, or their combination. Cell viability was assessed using CCK-8 assays. Western blotting evaluated Nrf2 pathway modulation. In vivo, LLC xenografts in C57BL/6 mice assessed tumor growth and kidney function. Results: The combination of HES with CDDP synergistically inhibited lung cancer cell viability in A549 and LLC cells compared to individual treatments (P < 0.05). This synergistic effect was associated with reduced Nrf2 pathway activation, enhancing oxidative stress sensitivity induced by CDDP. In vivo, HES + CDDP treatment significantly suppressed tumor growth in LLC xenograft mice, accompanied by alleviated CDDP-induced kidney injury, indicated by improved histopathology, reduced apoptosis, and restored antioxidant enzyme levels in kidney tissues. Conclusions: Combining HES with CDDP enhances LC treatment efficacy by synergistically inhibiting tumor growth and modulating the Nrf2 pathway. Additionally, HES protects against CDDP-induced kidney injury, suggesting potential benefits in LC treatment strategies.